New findings show that patients with moderate to severe plaque psoriasis treated with bimekizumab-bkzx (Bimzerx) rapidly achieved significantly higher clinical and health-related quality of life response rates through four years of treatment and subsequently Maintained.1
These findings were presented as an update at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego. The researchers pointed to several long-term findings showing bimekizumab’s effectiveness, including the observation that six out of 10 people treated had complete skin clearance after four years.
In a new interview at AAD HCP LiveMark G. Lebwohl, MD, spoke about the team’s latest data on the drug’s long-term efficacy and safety. Mr. Lebwohl is known for his contributions to psoriasis research and his role as chair of the Department of Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai.
“Bimekizumab is, of course, the most recent biologic drug approved in the United States for psoriasis,” Rebwohl said. “This is different from other biologics we have in that we have some biologics that block IL-17A and some that block the IL-17 receptor…IL Although -17A is certainly one of the most active cytokines that cause psoriasis, IL-17F is more prevalent in psoriatic skin lesions, and blocking both appears to have excellent effects. ”
Dr. Lebwohl described the Phase 3/3B studies from which these findings were derived, including the 52-week BE VIVID study, the 56-week BE READY and BE SURE studies, and the open-label extension study. . The open label extension (OLE) studies BE BRIGHT and BE RADIANT were also investigated by his Lebwohl.
“If you look at the percentage of people who received prior systemic therapy, it was over 80%, and the percentage who received prior biologic therapy was over 40%,” Rebwohl added. “So we are targeting a patient population that is very difficult to treat.”
The research team found that approximately 9 out of 10 people treated with bimekizumab achieved PASI90 at 16 weeks, and more than 7 out of 10 people who reported complete skin clearance maintained a response to bimekizumab. I discovered that it was shown that four years.
“If you look at the PASI100 score (corresponding 72.6%), imagine that nearly three-quarters of patients in the every 8-week group achieved PASI100 without any trace of psoriasis,” Rebwohl said. Stated. “64.7% of the group that had a poor response and maintained every-4-week dosing maintained a PASI of 100. In other words, nearly two-thirds of those who did poorly at week 52 did indeed achieve a PASI of 90. We achieved that.”
Lebwohl also discussed four years of safety data demonstrating that treatment-emergent adverse events (AEs) remained constant or decreased with longer exposure to treatment. There were no new safety signals.
To learn more about our findings, read the full interview above.
The quotes contained herein have been edited for clarity.
References
- Initial presentation at 4 years BIMZELX® (bimekizumab-bkzx) data demonstrated long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis. U.C.B. March 9, 2024. https://www.prnewswire.com/news-releases/first-presentation-of-year-4-bimzelx-bimekizumab-bkzx-data-showed-long-term-maintenance-of-complete-skin – Moderate to Severe Clearance of Plaque Psoriasis-302084576.html. Accessed: March 10, 2024.
